UNSPSC 51351502: Cismadinone

This classification denotes a therapeutic progestin with the molecular formula C21H27ClO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O00XM1O6TV, chemically known as 6 alpha-chloro-17-hydroxypregna-1,4-diene-3,20-dione. but generally known as cismadinone, which bears US NIH Compound Identifier 193990. European Medicines Agency schedules Cismadinone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07482MIG. The term CISMADINONE is an International Non-Proprietary Name.

UNSPSC 51351502 Cismadinone is a Commodity code covering generic pharmaceutical products supplied through state and local cooperative purchasing agreements. State and local governments procure generic multi-source pharmaceuticals and over-the-counter products for distribution across participating facilities, with recent solicitation activity driven by multistate cooperative purchasing alliances that aggregate demand across state agencies and member jurisdictions. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary issuing body under this code, leveraging cooperative vehicles to establish framework agreements with multiple pharmaceutical manufacturers and wholesalers. Vendors must comply with cGMP certification, Drug Supply Chain Security Act requirements, and FDA standards, and maintain relationships with authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) to deliver products through chargeback systems.

MMCAP's January 2026 RFP for generic multi-source pharmaceuticals and OTC products, with responses due March 26, 2026, represents the most recent relevant opportunity under this code. The solicitation covers multiple participating states including Minnesota and Oregon, with awarded contracts effective July 1, 2026, and a two-year term for new vendors with optional extensions. Evaluation weighting emphasizes price competitiveness at 75 percent, with secondary criteria including fixed pricing structure (10 percent), EDI capability and administrative fee compliance (5 percent each), and administrative data format compliance (5 percent). Vendors must maintain comprehensive insurance coverage, including commercial general liability of $5,000,000 per occurrence and network security liability of $2,000,000, and are subject to performance penalties ranging from $200 to $1,500 per violation for reporting failures or onboarding delays. The RFP does not disclose specific award values or budget ranges, though vendors are required to pay a 3 percent administrative fee on all contract purchases.